PUBLISHER: Grand View Research | PRODUCT CODE: 1869850
PUBLISHER: Grand View Research | PRODUCT CODE: 1869850
The global biologics contract development and manufacturing organization market size was estimated at USD 19.22 billion in 2024 and is projected to reach USD 42.32 billion by 2033, growing at a CAGR of 9.21% from 2025 to 2033. The market is driven by the rising prevalence of chronic and rare diseases, an aging global population, and the growing demand for highly targeted therapies.
Besides, with the increasing need for biologics, the pharmaceutical and biopharmaceutical industry continues to show a surge in the number of companies opting for CDMO services. Furthermore, growing investments in biologics are expected to drive venture capital, strategic collaborations, mergers, and acquisitions, further contributing to market growth across the value chain. Most pharmaceutical & biopharmaceutical companies are increasingly partnering with CDMO service providers to expand capacity and access specialized technologies, while private equity and institutional investors are expanding their funds into platform companies with innovative models. In addition, most large pharmaceutical companies are focusing on acquisitions to strengthen their biologics pipelines, diversify therapeutic portfolios, and secure advanced manufacturing capabilities. Thus, these capital investments and strategic innovations are accelerating commercialization and reshaping the competitive landscape and are expected to drive the market in the coming years.
Moreover, with the growing focus on regulatory scenarios, the U.S. FDA, EMA, and other global authorities are refining approval pathways for biosimilars, cell therapies, and gene-based treatments, creating guidelines to encourage innovation while safeguarding patient safety. In addition, harmonized standards across regions support streamlining submissions and reducing delays, while post-market surveillance & evidence requirements remain stringent in the market. The evolving regulatory environment significantly enables faster approvals for novel therapies while raising the compliance burden on developers to meet rigorous chemistry, manufacturing, and control expectations. Such factors are expected to drive the market over the estimated time period.
Global Biologics Contract Development And Manufacturing Organization Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biologics contract development and manufacturing organization (CDMO) market report based on product, service, source, workflow, therapeutic area, end use, and region: